Kane Biotech (CVE:KNE) Hits New 12-Month Low – Here’s What Happened

Kane Biotech Inc. (CVE:KNE)’s stock price reached a new 52-week low during trading on Wednesday . The company traded as low as C$0.03 and last traded at C$0.04, with a volume of 78503 shares trading hands. The stock had previously closed at C$0.03.

Kane Biotech Trading Up 16.7%

The firm has a market cap of C$5.82 million, a price-to-earnings ratio of -0.39 and a beta of 0.23. The company has a debt-to-equity ratio of -331.42, a quick ratio of 0.39 and a current ratio of 0.80. The company has a 50 day moving average price of C$0.04 and a 200 day moving average price of C$0.04.

Kane Biotech Company Profile

Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections.